Davenport & Co LLC
- SEC CIK
- 0000887777
- Latest filing
- Jul 13, 2026
NBSE holding history
NeuBase Therapeutics, Inc. in every 13F filed by Davenport & Co LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NBSE overviewAll 13F holders of NBSEFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −1,500−100.0% | Sold outConverted for a 1-for-20 split | Holders |
| Q1 2023 | 30,000 | $5.55K | <0.1% | −10,500−25.9% | Reduced | Holders |
| Q4 2022 | 40,500 | $7.70K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2022 | 40,500 | $16.0K | <0.1% | −5,000−11.0% | Reduced | Holders |
| Q2 2022 | 45,500 | $48.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 45,500 | $86.0K | <0.1% | −3,000−6.2% | Reduced | Holders |
| Q4 2021 | 48,500 | $136.0K | <0.1% | −10,000−17.1% | Reduced | Holders |
| Q3 2021 | 58,500 | $211.0K | <0.1% | +1,500+2.6% | Added | Holders |
| Q2 2021 | 57,000 | $273.0K | <0.1% | −2,500−4.2% | Reduced | Holders |
| Q1 2021 | 59,500 | $440.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.